RGD-functionalized cannabidiol lipid nanoparticles increased cellular uptake threefold and in-vitro BBB transport by 65%, while reducing inflammatory and oxidative markers. In a preclinical Alzheimer's model, cognition, Aβ/tau pathology, metabolism and gut-barrier indicators improved. The findings are promising but not evidence in patients.
Key findings
- Compared with non-targeted formulations, uptake rose threefold and BBB transport 65%. IL-6, TNF-α and ROS fell (p
Why this matters globally
Crossing the BBB and treating Alzheimer's as a brain-metabolic-gut system are global research priorities, giving this platform relevance to nanomedicine and systems biology.
Thai researcher contribution
A broad Thai university and NSTDA/NANOTEC collaboration combined neuroscience, metabolism, nanomaterials and pharmacology.
Limitations to consider
Evidence is cellular and animal-based; the abstract omits species, group size, randomization, blinding and dosing details. Animal models incompletely represent human disease, behavioural comparison with donepezil is not clinical equivalence, and long-term nanoparticle/CBD safety is unknown.